Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial

MLA

Reinhard Golz, et al. “Prostate-Specific Antigen Persistence after Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial.” International Journal of Radiation Oncology, Biology, Physics, vol. 91, no. 2, Aug. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a1f2483f04208870e76f965cfacf25c0&authtype=sso&custid=ns315887.

APA

Reinhard Golz, Horst-Jürgen Feldmann, Dirk Bottke, Axel Hinke, Detlef Bartkowiak, Michael Stöckle, Reinhard Thamm, Rainer Hofmann, Stephan Störkel, Wolfgang Hinkelbein, Manfred P. Wirth, Rita Engenhart-Cabillic, Thomas Wiegel, Alessandra Siegmann, Kurt Miller, T. Kälble, Axel Semjonow, Christian Rübe, & Ursula Steiner. (2014). Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. International Journal of Radiation Oncology, Biology, Physics, 91(2).

Chicago

Reinhard Golz, Horst-Jürgen Feldmann, Dirk Bottke, Axel Hinke, Detlef Bartkowiak, Michael Stöckle, Reinhard Thamm, et al. 2014. “Prostate-Specific Antigen Persistence after Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial.” International Journal of Radiation Oncology, Biology, Physics 91 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a1f2483f04208870e76f965cfacf25c0&authtype=sso&custid=ns315887.